Snakebite Drug Failed to Meet Primary Efficacy Endpoints
A Phase 2 trial of varespladib for snakebite patients did not reach its main goals despite some subgroup improvements.
Updated on Sept. 22, 2026 in Stroke
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparency when reporting mixed results from clinical trials?
Ophirex recently released results from its Phase 2 BRAVIO trial, which evaluated the experimental drug varespladib as an addition to standard antivenom. The study failed to meet its primary goals regarding time to recovery and overall illness severity for the 140 patients enrolled.
Why it matters
While the trial did not show a universal benefit, findings like these help researchers refine potential treatments for snake envenomation. Understanding why these outcomes varied is essential for future development of adjunct therapies that could eventually complement standard antivenom care.
In a Phase 2 randomized trial of 140 patients, varespladib was administered alongside standard antivenom but failed to meet primary endpoints for recovery time and severity. Subgroup analysis showed potential signals, but these remain preliminary findings.
The players
Ophirex
A pharmaceutical company focused on developing new treatments for snake envenomation.
The details
Varespladib acts by inhibiting sPLA2 enzymes, which are present in approximately 95% of venomous snake species and contribute to tissue damage. The trial involved intravenous and oral administration of the drug, given on average 7.3 hours after a bite. While the study did not meet its primary endpoints, krait patients receiving the drug saw reduced ventilation time and lower severity, as did copperhead patients, though these results were secondary measures.
Timeline
September 22, 2026: Ophirex announced the publication of the BRAVIO trial results.
Day 14: The final point for measuring the Snakebite Severity Score.
Health Landscape
This development reflects the ongoing challenges in identifying effective adjunct therapies for snake envenomation. It follows the regulatory pathway defined by the FDA's Animal Rule to advance treatments for conditions where traditional human efficacy trials are difficult to conduct.
This trial result does not change current standard care, which remains the prompt administration of antivenom. If you or someone you know sustains a snakebite, the most important action is to seek immediate emergency medical care rather than relying on experimental treatments.
The takeaway
While this trial did not reach its primary goals, it provides important data on the performance of sPLA2 inhibitors in diverse envenomation cases. Always prioritize recognized antivenom protocols and consult emergency professionals immediately following any venomous snakebite.
What happens next
Ophirex expects to publish further subgroup analyses regarding krait and copperhead bites in the coming months.
Further reading
For broader context on current clinical advancements, visit our Stroke section.
More information
Review the full Phase 2 clinical trial research paper for detailed study data.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparency when reporting mixed results from clinical trials?
